CMC Biologics has received renewal of its manufacturing and importation authorization (MIA) for cGMP production of clinical and commercial manufacturing following a successful inspection from the Danish Medicines Agency (DKMA). The DKMA inspected the company’s optimized manufacturing and testing facilities in Copenhagen, Denmark and issued the certificate based on the positive outcome.    “This important regulatory milestone helps drive our strategy to satisfy our customers’ growing ...